X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

CD24 Monoclonal Antibody (eBioSN3 (SN3 A5-2H10)), eFluor 450, eBioscience™

RRID:AB_11218707

Antibody ID

AB_11218707

Target Antigen

CD24 See NCBI gene human

Vendor

Thermo Fisher Scientific Go To Vendor

Cat Num

48-0247-41 also 48-0247

Proper Citation

(Thermo Fisher Scientific Cat# 48-0247-41, RRID:AB_11218707)

Reference

PMID:28092266

Clonality

monoclonal antibody

Clone ID

eBioSN3 (SN3 A5-2H10)

Host Organism

mouse

Comments

Applications: Flow (5 µL (0.25 µg)/test); Reactive Species: Human

Publications that use this research resource

TGF-β reduces DNA ds-break repair mechanisms to heighten genetic diversity and adaptability of CD44+/CD24- cancer cells.

  • Pal D
  • Elife
  • 2017 Jan 16

Literature context: -0247-42 (RRID:AB_11218707)


Abstract:

Many lines of evidence have indicated that both genetic and non-genetic determinants can contribute to intra-tumor heterogeneity and influence cancer outcomes. Among the best described sub-population of cancer cells generated by non-genetic mechanisms are cells characterized by a CD44+/CD24- cell surface marker profile. Here, we report that human CD44+/CD24- cancer cells are genetically highly unstable because of intrinsic defects in their DNA-repair capabilities. In fact, in CD44+/CD24- cells, constitutive activation of the TGF-beta axis was both necessary and sufficient to reduce the expression of genes that are crucial in coordinating DNA damage repair mechanisms. Consequently, we observed that cancer cells that reside in a CD44+/CD24- state are characterized by increased accumulation of DNA copy number alterations, greater genetic diversity and improved adaptability to drug treatment. Together, these data suggest that the transition into a CD44+/CD24- cell state can promote intra-tumor genetic heterogeneity, spur tumor evolution and increase tumor fitness.